SGLT (Sodium-Glucose Co-Transporter) Inhibitors Market: Competitive Landscape, Pipeline, and Market Analysis 2023

Purchase Option

$ 4000
$ 6600
$ 8900

Sodium-Glucose Co-Transporter (SGLT) is a member of the family of glucose transporters found in the human body. These play a significant function in reabsorbing glucose from the part in which they are present, depending upon the type of SGLT present. There are 2 types of SGLT present depending upon the location: SGLT-1 and SGLT-2. SGLT-1 is present in the brush border epithelium lined by the enterocytes, where it is responsible for glucose reabsorption from the intestine. SGLT-2 is present in the renal cortex, which absorbs glucose from the glomerular filtrate in the early and middle segments of the Proximal Convoluted Tubule (PCT).  These cotransporters play a significant role by regulating the glucose level in the body, hence, are a good target for drugs that aim to lower the blood glucose level in the body by indirect action, i.e., prevent absorption and increase excretion of glucose. Research is being conducted globally to discover new and novel molecules to be used as Anti-Diabetic agents. The development and launch of new products will thus increase the revenue of the market in the forecasted years. For instance, according to the International Diabetes Federation, in 2021, approximately 537 million people in the age bracket of 20-79 years globally are suffering from diabetes and counting. So, there is a huge market for the players to launch their products in the market in the near future.

A number of SGLT-1 inhibitors are on the market, while many are in ongoing clinical trials.  12 companies have various SGLT-1 inhibitors in their pipelines, with 8 products in various stages of clinical trials, 1 product in Phase 4, 1 product in Phase 3, 4 products in Phase 2, and 2 products in Phase 1 of the clinical trials. Moreover, 42 companies have various SGLT-2 Inhibitors in their pipelines, with 43 products in various stages of clinical trials, 17 products in Phase 4, 5 products in Phase 3, 4 products in Phase 2, and 12 products in Phase 1 of the clinical trials.

Key Developments

  • In Jue 2023, FDA approved Jardiance (empagliflozin) and Synjardy (empagliflozin and metformin HCl) as an adjuvant therapy to diet and exercise in children above 10 years of age and older with Type 2 diabetes.
  • In May 2023, dual SGLT-1/2 Inhibitor- Inpefa (sotagliflozin) was approved by the FDA to reduce the risk of cardiovascular deaths and hospitalization for Heart failure in adults.
  • In February 2023, Forxigo (dapagliflozin) was approved by the European Union (EU) to treat patients with Heart Failure with reduced ejection fraction.


Approved SGLT-1 Inhibitor drugs

  • Inpefa (sotagliflozin)

 SGLT-1 Inhibitor drugs in Pipeline

  • Licogliflozin (LIK066)
  • Mizagliflozin (VGX-3235)
  • Canalia (teneligliptin/canagliflozin)
  • SY-009
  • YG1699
  • SY-008
  • JTT-662
  • Approved SGLT-2 Inhibitor drugs
  • Farxiga (dapagliflozin)
  • Jardiance (empagliflozin)
  • Invokana (canagliflozin)
  • Inpefa (sotagliflozin)
  • Suglat (ipragliflozin)
  • Steglatro (ertugliflozin)
  • Synjardy (empagliflozin/metformin)
  • Enblo (enavogliflozin)
  • Qtern (dapagliflozin/saxagliptin)
  • Ruiqin (henagliflozin)
  • Xigduo (dapagliflozin and metformin extended-release)
  • Apleway (tofogliflozin)
  • Vokanamet (canagliflozin/immediate release metformin FDC)
  • Glyxambi (empagliflozin / linagliptin)
  • DA-2811
  • Lusefi (luseogliflozin
  • Steglujan (ertugliflozin/sitagliptin

SGLT-2 Inhibitor drugs in Pipeline

  • Brenzavvy (bexagliflozin)
  • Qtern (dapagliflozin/saxagliptin)
  • Remozen (remogliflozin etabonate)
  • Ruiqin (henagliflozin)
  • Xigduo (dapagliflozin and metformin extended-release)
  • Apleway (tofogliflozin)
  • licogliflozin (LIK066)
  • Vokanamet (canagliflozin/immediate release metformin FDC)
  • Glyxambi (empagliflozin / linagliptin)
  • rongliflozin (HEC44616)
  • DA-2811
  • Lusefi (luseogliflozin)
  • Steglujan (ertugliflozin/sitagliptin)
  • Sujanu (ipragliflozin/sitagliptin)
  • Trijardy XR (empagliflozin/linagliptin/metformin XR)
  • YG1699
  • CKD-378
  • MAR701
  • Qternmet XR (dapagliflozin/saxagliptin/metformin)
  • Segluromet (ertugliflozin/metformin)
  • dapagliflozin/sitagliptin
  • dapagliflozin/sitagliptin (SID1903)
  • henagliflozin/metformin (HR20033)
  • janagliflozin
  • pemafibrate/tofogliflozin (K-001)
  • pioglitazone/metformin/dapagliflozin (BR3003)
  • ISIS 388626
  • dapagliflozin/linagliptin (IN-C009)
  • dapagliflozin/metformin (HCP1801)
  • dapagliflozin/metformin/sitagliptin (GMRx4)
  • dapagliflozin/olmesartan medoxomil (ATB-101)
  • dapagliflozin/semaglutide (NN9917)
  • dapagliflozin/sitagliptin (DW6012)
  • enavogliflozin/gemigliptin (DWJ1563)
  • enavogliflozin/metformin (DWJ1525)

Clinical Activity and Developments of SGLT Inhibitors

As of June 2023, companies have approximately 8 products for 14 diseases. For these diseases, 7 trials are being conducted by players globally. For instance,

  • In July 2022, Youngene Therapeutics completed a Phase 2 clinical trial to study the comparison of postprandial glucose after a mixed meal tolerance test, and the metabolic effects of Insulin withdrawal in a crossover study of the dual systemic SGLT1and SGLT2 Inhibitor YG1699, and the selective SGLT2 Inhibitor Dapagliflozin in subjects with Type 1 Diabetes

SGLT-1 Inhibitor Molecule name

Number of studies

Inpefa (sotagliflozin)


licogliflozin (LIK066)


mizagliflozin (VGX-3235)


Canalia (teneligliptin/canagliflozin)





As of June 2023, 42 companies have approximately 43 products for 45 diseases. For these diseases, 393 trials are being conducted by players globally. For instance,

  • In May 2023, Columbia University completed a Phase 4 clinical trial to study empagliflozin in Transthyretin Amyloid (ATTR) cardiomyopathy.
  • In January 2023, Medanta, The Medicity completed a Phase 4 clinical trial to study the efficacy and safety of Dapagliflozin for the hospital management of patients with Type 2 Diabetes.
  • In October 2022, the University of Campinas completed a Phase 4 trial to study the pharmacokinetics and dialyzability of Dapagliflozin in dialysis patients

SGLT-2 Inhibitor Molecule name

Number of studies

Farxiga (dapagliflozin)


Jardiance (empagliflozin)


Invokana (canagliflozin)


Inpefa (sotagliflozin)


Suglat (ipragliflozin)



Target Indication Analysis of SGLT Inhibitors

Drugs like Jardiance and Farxiga have been approved by the FDA and other regulatory authorities for various indications and diseases. These are also in the clinical trials for other disorders and show encouraging results. SGLT Inhibitors are in clinical trials for many indications like Type 1 and Type 2 Diabetes Mellitus, Endocrine system diseases, Metabolic disorders, Hypertension, Atherosclerosis, and others. SGLT Inhibitors are also being tried to control body weight in obese patients, Hyperglycaemia, Hyperinsulinism, insulin resistance, and nutrition disorders. There is an excellent opportunity for the players of SGLT Inhibitors in the market with the rising prevalence of the diseases globally.

Frequently Asked Questions

Farxiga (dapagliflozin), Jardiance (empagliflozin) and Invokana (canagliflozin) are some of the SGLT-2 Inhibitors have been approved by the FDA while Inpefa (sotagliflozin) is the SGLT-1 Inhibitor approved by the FDA.

These are being used in various indications like Type 1 and Type 2 Diabetes Mellitus, Hypertension, Atherosclerosis, Endocrine system diseases, Metabolic diseases and others

Lexicon Pharmaceuticals, Novartis, Vogenx, Mitsubishi Tanabe and Daiichi Sankyo are some of the major market players for SGLT Inhibitors.

Rising incidence of diseases, improvement in technologies, development of new treatment lines in the market, and changing lifestyles leading to Diabetes Mellitus, Glucose intolerance, and metabolic disorders are the key opportunities for SGLT Inhibitors in the market.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • Lexicon Pharmaceuticals
  • Novartis
  • Vogenx
  • Mitsubishi Tanabe
  • Daiichi Sankyo
  • Youngene Therapeutics 
  • Japan Tobacco
  • Ono Pharma 
  • J&J
  • EMD Serono
  • Kotobuki
  • Astellas
  • Boehringer Ingelheim
  • Eli Lilly
  • GC Biopharma
  • M8 Pharma
  • TheracosBio
  • Islet Sci
  • Jiangsu Hengrui Pharma
  • Takeda
  • Novartis
  • Mundipharma 
  • HEC Pharm
  • Dong-A
  • Taisho 
  • Chong Kun Dang
  • Roche
  • Pfizer
  • Merck (MSD)
  • AstraZeneca
  • SK Bio
  • Sihuan Pharmaceutiical
  • Kowa
  • Boryung Group
  • Ionis
  • Korea Kolmar
  • Hanmi
  • George Medicines
  • Autotelic
  • Jeil
  • Novo Nordisk
  • Dong Wha
  • Daewoong Pharma

Adjacent Markets